ClinicalTrials.gg
TerminatedNCT03323749MMPOWER-3Updated Jan 24, 2022Results posted

A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension

A Phase 3 interventional study of elamipretide and placebo comparator in Primary Mitochondrial Myopathy, sponsored by Stealth BioTherapeutics Inc.. Terminated at 27 sites in 7 countries. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-01-24.

Sponsored by Stealth BioTherapeutics Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
Part1,double blind portion of the trial did not meet the primary end points

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
218
Allocation
Randomized
Ages
16 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 99 studies in Muscular Diseases with a site in United States — 19 open to participants now, 27 under way, 5 of them phase 3. Muscular Diseases · United States.

Enrollment
12th of 66
218 · median 38
Started
2017
with 4 others
Phase 3
14 of 99
1 open now
Registered
51st of 99
by date

Among the 99 studies in Muscular Diseases with a site in United States, this one is the 12th largest by enrollment of the 66 interventional ones that give a count, is one of 5 that started in 2017, is one of 14 in phase 3, and was the 51st registered.

Muscular Diseases

232 studies on the registry are indexed under Muscular Diseases; 54 are open to participants now.

Browse Muscular Diseases studies →

Open to participants now

19 of the 99 studies in Muscular Diseases with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Muscular Diseases studies recruiting now, 21 (55%) set no upper age limit and 10 (26%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.

This study: 16 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Muscular Diseases with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter phase 3 randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the safety and efficacy of daily subcutaneous injections of elamipretide in subjects with primary mitochondrial myopathy. This will be followed by an open-label treatment extension.

Read the detailed description

Part 11 is a 24-week, randomized, double-blind, parallel-group, placebo-controlled assessment of the efficacy and safety of single daily subcutaneous (SC) doses of 40 mg elamipretide (vs placebo) administered with the elamipretide delivery system as a treatment for subjects with primary mitochondrial myopathy (PMM). Part 2 was to assess the long-term safety and tolerability of single daily SC doses of 40 mg elamipretide administered with the elamipretide delivery system for up to 144 weeks.

03

Conditions studied

  • Primary Mitochondrial Myopathy

Browse trials for

Keywords

  • Myopathy
  • PMD
  • Primary Mitochondrial Disease
  • MTP-131
  • elamipretide
04

Who can participate

Ages eligible
16 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

PART 1:

Inclusion criteria

Inclusion Criteria:

  • Willing and able to provide a signed form prior to participation in any trial-related procedures
  • Agrees to adhere to the trial requirements for the length of the trial, including the use of the elamipretide delivery system
  • Subject is ≥ 16 and ≤ 80 years of age
  • Diagnosed with PMM in the opinion of the investigator and confirmed by an Adjudication Committee
  • Woman of must agree to use a highly effective method of

Exclusion criteria

Exclusion Criteria:

  • Subject has myopathic signs and or/symptoms due to a neuropathic process or gait problem that would interfere with the 6 minute walk test (6MWT), in the opinion of the Investigator
  • Female who are pregnant, planning to become pregnant, or breastfeeding/lactating
  • At Screening, the estimated (eGFR) \< 30 mL/min/1.73 m\^2
  • Subject has undergone an in-patient hospitalization within the 30 days prior to the Baseline Visit or has a planned hospitalization or a surgical procedure during the trial.
  • Subject has cardiac disease or prior interventional procedure and/or respiratory disease (medical history or current clinical findings) within 3 months of the Baseline Visit, in the opinion of the Investigator.
  • Subject has elongation (using the correction factor utilized at the clinical site) defined as a QTc >450 msec in male subjects and >480 msec in female subjects.
  • evidence of acute ischemia, atrial fibrillation, or active conduction system abnormalities with the exception of any of the following:

    1. First degree Atrioventricular bock (AV-block)
    2. Second degree AV-block Type 1 (Mobitz Type 1 / Wenckebach type)
    3. Right bundle branch block
  • Subject has severe vision impairment that, in the opinion of the Investigator, may interfere with their ability to complete all trial requirements
  • Subject has a seizure disorder that, in the opinion of the Investigator, may interfere with their ability to complete all trial requirements.
  • Active or any other cancer from which the subject has been disease-free for \< 2 years.
  • Subject has a solid organ transplant and/or is currently receiving treatment with therapy for , in the opinion of the Investigator.
  • Subject has been previously diagnosed with (HIV), , or infection.
  • Subject has a history of a systemic eosinophilic illness and/or an eosinophil count >1,000 cells x10\^6/L at the Screening Visit.
  • Subject is currently participating or has participated in an interventional clinical trial (i.e., product or device, stem cell therapy, gene therapy) within 30 days of the Baseline Visit; or is currently enrolled in a non-interventional clinical trial (except for SPIMM-300) at the Baseline Visit which, in the opinion of the Investigator, may be potentially confounding with results of the current trial (e.g., exercise therapy trial).
  • Subject has previously received elamipretide (MTP-131), for any reason.
  • Subject has a history of active substance abuse during the year before the Baseline Visit, in the opinion of the Investigator.
  • Subject has any prior or current medical condition that, in the judgment of the Investigator, would prevent the subject from safely participating in and/or completing all trial requirements.

PART 2:

Continuation Criteria:

  • Subjects must continue to be able and willing to adhere to the trial requirements.
  • Subject is appropriate to continue in Part 2 (i.e. subject was compliant in Part 1), in the opinion of the Investigator.
  • Subject has not had a serious adverse event (SAE)/serious adverse device effect (SADE) attributed to the elamipretide delivery system.
  • Subject has not permanently discontinued the elamipretide delivery system.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
218 participants (actual)

Study arms

  • Experimental
    Part 1: Elamipretide

    40 mg (0.5mL) elamipretide subcutaneous (SC) daily

    Combination Product: elamipretide

  • Placebo comparator
    Part 1: Placebo

    Placebo SC daily

    Combination Product: placebo comparator

  • Experimental
    Part 2: Elamipretide open label

    Elamepretide 40 mg (0.5 mL) SC daily

    Combination Product: elamipretide open label treatment

Interventions

  • Combination productelamipretide

    40 mg of elamipretide administered as once daily 0.5 mL subcutaneous injections for 24 weeks using the elamipretide delivery system

    Also known as: MTP-131

  • Combination productplacebo comparator

    40 mg of placebo administered as once daily 0.5 mL subcutaneous injections for 24 weeks using the elamipretide delivery system

    Also known as: Placebo

  • Combination productelamipretide open label treatment

    40 mg of elamipretide administered as once daily 0.5 mL subcutaneous injections for up to 144 weeks using the elamipretide delivery system

06

What researchers measure

Primary outcomes

  1. Six-minute Walk Test (6MWT)

    Change From Baseline in Distance Walked (meters) on the Six-Minute Walk Test by Visit

    Time frame: Baseline to 24 weeks

  2. Total Fatigue Score on the on the Primary Mitochondrial Myopathy Symptom Assessment (PMMSA)

    Change from Baseline in Total fatigue score on the on the Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) by visit. Each individual item score ranges from 1 (none) to 4 (severe). The total fatigue score ranges from 4-16. Lower values represent a better outcome. The total fatigue score is the sum of question 1 through question 4 on the Primary Mitochondrial Myopathy Symptom Assessment.

    Time frame: Baseline to 24 weeks

Secondary outcomes

  1. Fatigue During Activities Score on the Primary Mitochondrial Disease Symptom Assessment (PMMSA).

    Change from baseline in Fatigue During Activities. Fatigue During Activities is the sum of question 2 (tiredness during activities) and question 4 (muscle weakness during activities.) The four response options are: 1=Not at all, 2=Mild, 3=Moderate, and 4=Severe. Raw scores for each subject range from 2-8. A lower score means a better outcome, with less fatigue. A higher score means a worse outcome, with more fatigue.

    Time frame: Baseline to 24 weeks

  2. Neuro-QoL Fatigue Activities of Daily Living

    Change From Baseline in Neuro-QoL Fatigue Activities of Daily Living by Visit. Each individual item score ranges from 1-5. Total raw score for the entire item bank ranges from 19-95. Raw scores will be calibrated using Item Response Theory Model. Lower values represent a better outcome. Individual items will be summed to calculate total scores.

    Time frame: Baseline to 24 weeks

  3. Change From Baseline in the Most Bothersome Symptom Score on the Primary Mitochondrial Myopathy Symptoms Assessment

    The item score rangers from 1 (none) to 4 (severe). Lower values represent a better outcome. The most bothersome score is the average of the identified most bothersome symptom of the Primary Mitochondrial Myopathy Symptom Assessment by each subject.

    Time frame: Baseline to 24 weeks

  4. Neuro-QoL Fatigue Short Form Score

    Change From Baseline in Neuro-QoL Fatigue - Short Form: Total T-Scores by Visit. The Neuro-QoL Fatigue Short Form is comprised of the sum of the first 8 questions of the Neuro-QoL Item Bank v1.0 - Fatigue. Each question is scored as following: 1=Never, 2=Rarely, 3=Sometimes, 4=Often, and 5=Always. The questions include: I felt exhausted, I felt that I had no energy, I felt fatigued, I was too tired to do my household chores, I was too tired to leave the house, I was frustrated by being too tired to do the things I wanted to do, I felt tired, and I had to limit my social activity because I was tired. T-scores are calculated from the short form scoring table provided by the instrument authors (Neuro-QoL User Manual, 2015). T-score distributions rescale raw scores into standardized scores with a mean of 50 and a standard deviation (SD) of 10. Change from baseline: Negative numbers mean less fatigue, better outcome, positive score means more fatigue, worse outcome.

    Time frame: 24 Weeks

07

Results

Posted Apr 2, 2021

Participant flow

Double-blind Period
Participant flow — Double-blind Period
MilestoneDouble-Blind Elamipretide, Then Open Label ElamepretideDouble-Blind Placebo Then Open-Label Elamepretide
Started109109
Completed102103
Not completed76
Withdrew: Lost to follow-up45
Withdrew: Adverse event31
Open-Label Period
Participant flow — Open-Label Period
MilestoneDouble-Blind Elamipretide, Then Open Label ElamepretideDouble-Blind Placebo Then Open-Label Elamepretide
Started93103
Completed00
Not completed93103
Withdrew: Termination of the clinical development of elamipretide in subjects with pmm8388
Withdrew: Adverse event310
Withdrew: Withdrawal by subject75

Outcome measures

PrimarySix-minute Walk Test (6MWT)

Change From Baseline in Distance Walked (meters) on the Six-Minute Walk Test by Visit

Time frame:
Baseline to 24 weeks
Reported as:
Mean · meters
Six-minute Walk Test (6MWT)
metersElamipretidePlacebo
Week 416.243 ± 42.00717.811 ± 39.5737
Week 1218.286 ± 47.77668.801 ± 52.1093
Week 2415.330 ± 61.486017.386 ± 51.6956
PrimaryTotal Fatigue Score on the on the Primary Mitochondrial Myopathy Symptom Assessment (PMMSA)

Change from Baseline in Total fatigue score on the on the Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) by visit. Each individual item score ranges from 1 (none) to 4 (severe). The total fatigue score ranges from 4-16. Lower values represent a better outcome. The total fatigue score is the sum of question 1 through question 4 on the Primary Mitochondrial Myopathy Symptom Assessment.

Time frame:
Baseline to 24 weeks
Reported as:
Mean · score on a scale
Total Fatigue Score on the on the Primary Mitochondrial Myopathy Symptom Assessment (PMMSA)
score on a scaleElamipretidePlacebo
Week 4-1.01 ± 1.714-1.08 ± 1.865
Week 12-1.08 ± 1.775-1.26 ± 2.259
Week 24-1.18 ± 2.132-1.09 ± 2.443
SecondaryFatigue During Activities Score on the Primary Mitochondrial Disease Symptom Assessment (PMMSA).

Change from baseline in Fatigue During Activities. Fatigue During Activities is the sum of question 2 (tiredness during activities) and question 4 (muscle weakness during activities.) The four response options are: 1=Not at all, 2=Mild, 3=Moderate, and 4=Severe. Raw scores for each subject range from 2-8. A lower score means a better outcome, with less fatigue. A higher score means a worse outcome, with more fatigue.

Time frame:
Baseline to 24 weeks
Reported as:
Mean · score on a scale
Fatigue During Activities Score on the Primary Mitochondrial Disease Symptom Assessment (PMMSA).
score on a scaleElamipretidePlacebo
Week 4-0.48 ± 0.890-0.60 ± 0.998
Week 12-0.57 ± 0.923-0.67 ± 1.199
Week 24-0.64 ± 1.151-0.59 ± 1.360
SecondaryNeuro-QoL Fatigue Activities of Daily Living

Change From Baseline in Neuro-QoL Fatigue Activities of Daily Living by Visit. Each individual item score ranges from 1-5. Total raw score for the entire item bank ranges from 19-95. Raw scores will be calibrated using Item Response Theory Model. Lower values represent a better outcome. Individual items will be summed to calculate total scores.

Time frame:
Baseline to 24 weeks
Reported as:
Mean · score on a scale
Neuro-QoL Fatigue Activities of Daily Living
score on a scaleElamipretidePlacebo
Week 4-2.5 ± 5.33-2.7 ± 5.31
Week 12-2.9 ± 6.00-2.9 ± 5.13
Week 24-2.7 ± 6.06-2.1 ± 5.39
SecondaryChange From Baseline in the Most Bothersome Symptom Score on the Primary Mitochondrial Myopathy Symptoms Assessment

The item score rangers from 1 (none) to 4 (severe). Lower values represent a better outcome. The most bothersome score is the average of the identified most bothersome symptom of the Primary Mitochondrial Myopathy Symptom Assessment by each subject.

Time frame:
Baseline to 24 weeks
Reported as:
Mean · score on a scale
Change From Baseline in the Most Bothersome Symptom Score on the Primary Mitochondrial Myopathy Symptoms Assessment
score on a scaleElamipretidePlacebo
Week 4-0.21 ± 0.492-0.24 ± 0.535
Week 12-0.24 ± 0.535-0.34 ± 0.656
Week 24-0.25 ± 0.618-0.30 ± 0.713
SecondaryNeuro-QoL Fatigue Short Form Score

Change From Baseline in Neuro-QoL Fatigue - Short Form: Total T-Scores by Visit. The Neuro-QoL Fatigue Short Form is comprised of the sum of the first 8 questions of the Neuro-QoL Item Bank v1.0 - Fatigue. Each question is scored as following: 1=Never, 2=Rarely, 3=Sometimes, 4=Often, and 5=Always. The questions include: I felt exhausted, I felt that I had no energy, I felt fatigued, I was too tired to do my household chores, I was too tired to leave the house, I was frustrated by being too tired to do the things I wanted to do, I felt tired, and I had to limit my social activity because I was tired. T-scores are calculated from the short form scoring table provided by the instrument authors (Neuro-QoL User Manual, 2015). T-score distributions rescale raw scores into standardized scores with a mean of 50 and a standard deviation (SD) of 10. Change from baseline: Negative numbers mean less fatigue, better outcome, positive score means more fatigue, worse outcome.

Time frame:
24 Weeks
Reported as:
Mean · score on a scale
Neuro-QoL Fatigue Short Form Score
score on a scaleElamipretidePlacebo
Week 4-3.37 ± 5.077-2.89 ± 5.915
Week 12-3.43 ± 5.681-3.60 ± 5.614
Week 24-2.68 ± 5.769-2.61 ± 5.773

Adverse events

Collected over Double-blind period: 24 weeks and continued with Open-label period: up to 144 weeks.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-Blind Elamipretide0/109 (0%)5/109 (4.6%)107/109 (98.2%)
Double-Blind Placebo0/109 (0%)3/109 (2.8%)83/109 (76.1%)
Open-Label Elamipretide0/93 (0%)12/93 (12.9%)88/93 (94.6%)
Open-Label Placebo0/103 (0%)9/103 (8.7%)102/103 (99%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventDouble-Blind ElamipretideDouble-Blind PlaceboOpen-Label ElamipretideOpen-Label Placebo
Cerebrovascular accidentNervous system disorders0/1090/1090/932/103
Suicidal IdeationPsychiatric disorders1/1090/1091/930/103
Psychogenic seizureNervous system disorders0/1090/1091/930/103
Intervertebral disc disorderMusculoskeletal and connective tissue disorders0/1090/1091/930/103
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/1090/1091/930/103
Humerus fractureInjury, poisoning and procedural complications0/1090/1091/930/103
AsthmaRespiratory, thoracic and mediastinal disorders0/1090/1091/930/103
Acute myocardial infarctionCardiac disorders0/1090/1091/930/103
Coronary artery dissectionCardiac disorders0/1090/1091/930/103
Chest painGeneral disorders0/1090/1091/930/103
Most frequent other events
Showing 10 of 45
Most frequent other events
EventDouble-Blind ElamipretideDouble-Blind PlaceboOpen-Label ElamipretideOpen-Label Placebo
Injection site erythemaGeneral disorders94/10931/10966/9387/103
Injection site pruritusGeneral disorders82/10910/10957/9381/103
Injection site indurationGeneral disorders31/1096/10925/9341/103
Injection site painGeneral disorders43/10920/10932/9337/103
Injection site swellingGeneral disorders42/1097/10929/9320/103
injection site bruisingGeneral disorders9/10918/1095/9315/103
injection site urticariaGeneral disorders14/1090/10912/938/103
injection site noduleGeneral disorders11/1092/1098/938/103
injection site haemorrhageGeneral disorders7/10910/1092/938/103
EosinophiliaBlood and lymphatic system disorders0/1090/1091/939/103

Baseline characteristics

Age, Customized
Age, Customized(years)ElamipretidePlaceboTotal
Years, Double-blind45.5 ± 15.7244.3 ± 14.3444.9 ± 15.02
Years, Open-label45.7 ± 15.9745.0 ± 14.2545.3 ± 15.05
Sex: Female, Male
Sex: Female, Male(Participants)ElamipretidePlaceboTotal
Double-Blind Sex — Female6773140
Double-Blind Sex — Male423678
Open-Enrollment Sex — Female5667123
Open-Enrollment Sex — Male373673
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ElamipretidePlaceboTotal
Ethnicity Double-Blind — Hispanic or Latino111021
Ethnicity Double-Blind — Not Hispanic or Latino9596191
Ethnicity Double-Blind — Unknown or Not Reported336
Ethnicity Open-Label — Hispanic or Latino81018
Ethnicity Open-Label — Not Hispanic or Latino8291173
Ethnicity Open-Label — Unknown or Not Reported325
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ElamipretidePlaceboTotal
Double-blind Period — American Indian or Alaska Native101
Double-blind Period — Asian257
Double-blind Period — Native Hawaiian or Other Pacific Islander000
Double-blind Period — Black or African American101
Double-blind Period — White103100203
Double-blind Period — More than one race213
Double-blind Period — Unknown or Not Reported033
Open-label period — American Indian or Alaska Native101
Open-label period — Asian044
Open-label period — Native Hawaiian or Other Pacific Islander000
Open-label period — Black or African American101
Open-label period — White8995184
Open-label period — More than one race213
Open-label period — Unknown or Not Reported033
Weight (kg)
Weight (kg)(kg)ElamipretidePlaceboTotal
Double-blind64.81 ± 20.28767.24 ± 17.33666.02 ± 18.865
Open-label65.66 ± 20.86768.01 ± 17.23766.89 ± 19.033
08

Study locations

27 sites
  • University of California San Diego
    La Jolla, California 92093, United States
  • Stanford University
    Palo Alto, California 94304, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Rare Disease Research, LLC
    Atlanta, Georgia 30318, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Akron Children's Hospital
    Akron, Ohio 44308, United States
  • Cleveland Clinical Neurological Institute
    Cleveland, Ohio 44195, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Children's Hospital of Pittsburgh of UPMC
    Pittsburgh, Pennsylvania 15224, United States
  • Baylor College of Medicine/Texas Children's Hospital
    Houston, Texas 77030, United States
  • University of Texas Health Science Center
    Houston, Texas 77030, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Adult Metabolic Diseases Clinic
    Vancouver, British Colombia, Canada
  • McMaster University Medical Center
    Hamilton, Ontario, Canada
  • Copenhagen Neuromuscular Center
    Copenhagen, DK-2100, Denmark
  • University Hospital of Bonn
    Bonn, 53105, Germany
  • Klinikum der Universität München, Friedrich-Baur Institute
    Munich, 80336, Germany
  • Institute of Genomic Medicine and Rare Disorders
    Budapest, 1083, Hungary
  • IRCCS Institute of Neorological Sciences of Bologna, Bellaria Hospital
    Bologna, 40139, Italy
  • Azienda Ospedaliero Universitaria Policlinico G. Martino
    Messina, 98125, Italy
  • Istituto Nazionale Neurologico Carlo Besta
    Milan, 20133, Italy
  • Dipartimento Ambientale di Neuroscienze
    Pisa, 56126, Italy
  • Ospedale Pediatrico Bambin Gesù
    Rome, 00165, Italy
  • Istituto di Neurologia, Fondazione Policlinico Universitario A. Gemelli
    Rome, 00168, Italy
  • MRC Centre for Neuromuscular Diseases
    London, United Kingdom
  • Royal Victoria Infirmary
    Newcastle Upon Tyne, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Feb 2020, 28 months.

Results were first posted in Apr 2021, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2017
First posted
Oct 27, 2017
StartActual
Oct 9, 2017
Primary completionActual
Feb 10, 2020
CompletionActual
Feb 10, 2020
Results first posted
Apr 2, 2021
Last update
Jan 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03323749
Responsible party
Sponsor
First posted
Oct 27, 2017
Start date
Oct 9, 2017
Primary completion
Feb 10, 2020
Completion
Feb 10, 2020
Results posted
Apr 2, 2021
Last update
Jan 24, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elamipretide

Start the discussion